Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Marcio M Andrade-Campos, MD PhD, Lierni Fernández-Ibarrondo, Joan Gibert, PhD, Concepción Fernández, Brayan Merchan, MD, Nieves García Gisbert, BSc, Laura Camacho, Leonor Arenillas, MD PhD, Sara García Ávila, MD, Raquel Longarón, Antonio Salar, MD PhD, Carles Besses, MD PhD, Beatriz Bellosillo, PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142705

Published: 2020

Journal Articles

Molecular Characterization of Ph-Negative Myeloproliferative Neoplasms in Tumor Circulating Nucleic Acids

Nieves Garcia-Gisbert, MSc, Lierni Fernández-Ibarrondo, Concepción Fernández-Rodríguez, Laura Camacho, Anna Angona, MD PhD, Joan Gibert, PhD, Xavier Calvo, MD PhD, Leonor Arenillas, MD PhD, Raquel Longarón, Marcio Andrade, MD PhD, Antonio Salar, MD PhD, Carles Besses, MD PhD, Beatriz Bellosillo, PhD

Blood (2019) 134 (Supplement_1): 2953.

https://doi.org/10.1182/blood-2019-123003

Published: 2019

Journal Articles

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

Blood (2018) 132 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2018-99-119221

Published: 2018

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

Does PDG-PET Add Additional Prognostic Information to CT Staging in Lymphoma Patients?

Blanca Sanchez-Gonzalez, MD, PhD, Carlos Trampal, MD, Alberto Solano, MD, Carmen Pedro, MD, Jm Maiques, MD, Alberto Alvarez, MD, PhD, Eva Gimeno, MD, Eugenia Abella, MD, PD, Carles Besses, MD, PhD, Antonio Salar, MD, PhD

Blood (2008) 112 (11): 4949.

https://doi.org/10.1182/blood.V112.11.4949.4949

Published: 2008

Journal Articles

Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V 617F Status

Eulalia Puigdecanet, Blanca Espinet, PhD, Juan Jose Lozano, PhD, Lauro Sumoy, PhD, Beatriz Bellosillo, PhD, Miquel Granell, MD, Alberto Alvarez-Larrán, MD, PhD, Leonor Arenillas, MD, Francesc Sole, PhD, Sergi Serrano, MD, PhD, Francisco Cervantes, MD, PhD, Carles Besses, MD, PhD, Lourdes Florensa, MD, PhD

Blood (2008) 112 (11): 2788.

https://doi.org/10.1182/blood.V112.11.2788.2788

Published: 2008

Journal Articles

Analysis of JAK2V617F Mutation, PRV-1 Overexpression and Endogenous Erythroid Colony (EEC) Formation Show Different Coexpression Patterns among Ph-Negative Chronic Myeloproliferative Disorders.

Beatriz Bellosillo, PhD, Carles Besses, MD, PhD, Lourdes Florensa, MD, PhD, Raquel Longaron, Gemma Navarro, Eva Gimeno, MD, Francesc Sole, PhD, Rosa M. Vila, Sergi Serrano, MD, PhD

Blood (2005) 106 (11): 2592.

https://doi.org/10.1182/blood.V106.11.2592.2592

Published: 2005

NARROW

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Molecular Characterization of Ph-Negative Myeloproliferative Neoplasms in Tumor Circulating Nucleic Acids

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Does PDG-PET Add Additional Prognostic Information to CT Staging in Lymphoma Patients?

Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V 617F Status

Analysis of JAK2V617F Mutation, PRV-1 Overexpression and Endogenous Erythroid Colony (EEC) Formation Show Different Coexpression Patterns among Ph-Negative Chronic Myeloproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Molecular Characterization of Ph-Negative Myeloproliferative Neoplasms in Tumor Circulating Nucleic Acids

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Does PDG-PET Add Additional Prognostic Information to CT Staging in Lymphoma Patients?

Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V 617F Status

Analysis of JAK2V617F Mutation, PRV-1 Overexpression and Endogenous Erythroid Colony (EEC) Formation Show Different Coexpression Patterns among Ph-Negative Chronic Myeloproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only